↓ Skip to main content

Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

Overview of attention for article published in Cancer Chemotherapy and Pharmacology, June 2019
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
44 Mendeley
Title
Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody–drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII
Published in
Cancer Chemotherapy and Pharmacology, June 2019
DOI 10.1007/s00280-019-03879-2
Pubmed ID
Authors

Mark Rosenthal, Richard Curry, David A. Reardon, Erik Rasmussen, Vijay V. Upreti, Michael A. Damore, Haby A. Henary, John S. Hill, Timothy Cloughesy

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 44 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 16%
Student > Master 6 14%
Student > Ph. D. Student 5 11%
Student > Bachelor 4 9%
Other 3 7%
Other 2 5%
Unknown 17 39%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 14%
Medicine and Dentistry 6 14%
Pharmacology, Toxicology and Pharmaceutical Science 5 11%
Immunology and Microbiology 4 9%
Neuroscience 2 5%
Other 5 11%
Unknown 16 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2019.
All research outputs
#21,164,509
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#2,211
of 2,501 outputs
Outputs of similar age
#300,703
of 351,667 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#23
of 32 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 351,667 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.